+

WO1999011799A2 - Gene d'aminopeptidase p humaine - Google Patents

Gene d'aminopeptidase p humaine Download PDF

Info

Publication number
WO1999011799A2
WO1999011799A2 PCT/US1998/018426 US9818426W WO9911799A2 WO 1999011799 A2 WO1999011799 A2 WO 1999011799A2 US 9818426 W US9818426 W US 9818426W WO 9911799 A2 WO9911799 A2 WO 9911799A2
Authority
WO
WIPO (PCT)
Prior art keywords
seq
human
protein
aminopeptidase
cells
Prior art date
Application number
PCT/US1998/018426
Other languages
English (en)
Other versions
WO1999011799A3 (fr
Inventor
James W. Ryan
Terry Joe Curtis Sprinkle
Richard C. Venema
Original Assignee
Medical College Of Georgia Research Institute, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medical College Of Georgia Research Institute, Inc. filed Critical Medical College Of Georgia Research Institute, Inc.
Priority to AU93034/98A priority Critical patent/AU9303498A/en
Publication of WO1999011799A2 publication Critical patent/WO1999011799A2/fr
Publication of WO1999011799A3 publication Critical patent/WO1999011799A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)

Definitions

  • BK bradykinin
  • ACE angiotensin converting enzyme
  • pig kidney extracts contained a particulate-associated AmP activity and that the AmP -like substance was not solubilized by detergents (78).
  • the AmP -like material believed to have been solubilized in a butanol/aqueous solvent system, behaved like a complex mixture of substances on chromatography.
  • pig kidney AmP did not hydrolyze polyproline, the substrate used to assay E. coli AmP.
  • a weakly reactive synthetic substrate was prepared, Gly-Pro-Hyp, and AmP activity was measured in terms of the rate of formation of free glycine in a two-step assay protocol (78).
  • Hooper et al solved the problem of solubilizing pig kidney AmP. They found that AmP is bound to membranes via a glycosyl phosphatidylinositol (GPI) lipid anchor and can be solubilized efficiently using phosphatidylinositol-specific phospholipase C (PI-PLC). Subsequently, Simmons et al (180) and Ryan, et al. (32) showed that rat and bovine lung and guinea pig lung and kidney forms of AmP are solubilized by PI-PLC. Human kidney AmP is also solubilized by PI-PLC. Once thus solubilized, AmP no longer behaves anomalously on conventional chromatography matrices.
  • GPI glycosyl phosphatidylinositol
  • Aminopeptidase P (AmP; EC 3.4.11.9) is the only known human enzyme capable of hydrolyzing a N-terminal imido bond, a bond common to many collagen degradation products and some neuropeptides, cytokines and vasoactive peptides (14,16,21,22,31,98,111,146,147,152,165,192,205). AmP occurs in cell membrane-bound and intracellular soluble forms and is not uniformly distributed among tissues nor among cell-types of a given tissue (21,39, 165,205), which implies that physiologic roles of AmP are determined by anatomic disposition (a determinant of reaction conditions and access to substrates) as well as by catalytic selectivity.
  • the genomic DNA and full-length cDNA sequence of human kidney AmP has been determined.
  • the deduced amino acid sequence indicates that AmP is a member of the recently-recognized "pita bread-fold” protein family, a family of very little sequence homology but of high similarity in three-dimensional structure (59).
  • pita bread-fold a subdivision of the "proline peptidase” family, with which human kidney AmP shares at least five short blocks of amino acid sequences of fair to high homology (although overall homologies are low). These blocks are known to contain the amino acid residues that compose the catalytic site of E.
  • coli methionine aminopeptidase a metallo-peptidase whose structure has been determined by x-ray crystallography (59). Based on these comparisons, it is postulated that human kidney AmP amino acid residue H430 serves as the proton shuttle, and D450, D461, H520, E555 and E569 (see SEQ ID NO:2) are the catalytic metal ligands. This can be tested by preparing the site-specific mutants H430F, D450N, D461N, H520F, E555Q and E569Q.
  • each of five potential N-glycosylation sites and each of five C residues can be mutated to examine for indirect effects of glycosyl groups and disulfide bonds on catalytic activity, solubility and protein stability.
  • EM electron microscopy
  • the inferred amino acid sequence can be used as a starting point for defining higher structure and function. Through protein expression, crystals can be prepared for determination of higher structure. Reverse transcriptase-polymerase chain reactions was used to obtain four overlapping fragments of AmP cDNA. The intact full-length cDNA can be obtained by ligation. The first (nt 1-474) and second (359- 734) fragments are digested with XmnI (nt 365) and then ligated.
  • DNA encoding human AmP can also be produced by direct synthesis of appropriate oligonucleotides based on the disclosed amino acid and nucleotide sequences.
  • the full-length DNA is transferred into the expression vector pVL1393 and used with co- transfectant, Baculogold, in the baculovirus/Sf9 insect cell system. This system has the capacity to produce recombinant AmP in the amounts needed for x-ray crystallography.
  • AmP disposed in the endoplasmic reticulum of, for example, lymphocytes is expected to have functions and reaction conditions different from ectoenzyme forms disposed on renal proximal tubule and small intestine brush border epithelia and different yet again from AmP disposed on the luminal surface of vascular endothelium.
  • Oligonucleotide probes and primers can be used to identify patients with homozygous or heterozygous AmP deficiencies. Primers can be used to examine for faulty AmP mRNA. Two pediatric patients with apparent homozygous deficiencies have been identified, at least one of which was mentally-retarded, epileptic and microcephalic. Early gene therapy could moderate any central nervous system injuries attributable to the lack of AmP, if administered early enough. Prenatal diagnosis of an AmP deficiency state would help decision making by parents and health care providers.
  • human AmP As a member of the so-called "pita bread-fold" protein family, human AmP has a recognizable putative proton shuttle and five putative metal ligands. With molecular modelling, and expressed protein, one can design inhibitors of AmP. Since AmP inactivates the blood pressure-lowering oligopeptide bradykinin, inhibitors of AmP could be useful as antihypertensive agents. Bradykinin is reported to be antimitogenic and antiatherogenic. Thus, inhibition of AmP (and concomitant preservation of bradykinin) should be useful in preventing or limiting arterial stenosis or restenosis and development of atherosclerosis.
  • the structure of AmP can be used to design synthetic substrate, which in turn can be used to develop diagnostic assays based on AmP catalytic activity. These substrates and others will be of value, along with recombinant AmP, for screening of drugs designed to inhibit AmP.
  • AmP is a protease capable of hydrolyzing N-terminal imido bonds it should be useful in degrading industrial protein feedstocks to free amino acids, and in breaking down wastes that have significant protein content, especially proline-rich collagenous protein wastes (wastes that are otherwise resistant to degradation by better-known enzymes such as trypsin and chymotrypsin). In so-called intestinal malabsorption syndromes, patients are sometimes given encapsulated digestive enzymes to improve breakdown of foodstuffs. AmP should be a beneficial additive to the mix of encapsulated enzymes to facilitate breakdown of proline-rich peptides.
  • Human AmP cDNA and genomic DNA can be used for designing antisense oligonucleotides, which may, in turn, be useful in patients having a surplus of AmP that, for example, contributes to arterial stenosis or restenosis or that contributes to development of atherosclerosis.
  • AmP inhibitors By analogy with uses of AmP inhibitors, some downward modulation of AmP activity via use of antisense nucleotides might provide antihypertenstive effects.
  • Human AmP cDNA and genomic DNA can be used to develop transgenic animal models and can be used, under low stringency conditions, to clone AmP cDN As and genomic DN As of other animal species. By the latter means, knockout animal models can be prepared and provided commercially to other investigators.
  • the AmP cDNA and genomic DNA can also be used to prepare stable transformants that can be provided commercially to other investigators. With knowledge of the AmP DNA sequence and its coding for putative critical amino acid residues of the catalytic site, mutants can be prepared to modulate catalytic activity.
  • unglycosylated, truncated forms of AmP can be expressed that are catalytically active but more amenable than wild-type AmP to crystallization. Such forms should be highly useful to drug design firms.
  • ACE angiotensin converting enzyme
  • HL510 binds human AmP (32).
  • the anti-AmP preparations have proved to have many uses and have been particularly helpful in immuno affinity chromatography. Immunoaffinity chromatography has substantially simplified the task of purifying AmP and yields apparently pure AmP in the mole quantities needed for structure studies.
  • HL510 has also been used for light microscopy immunocytochemistry. In guinea pigs, spleen, kidney, liver, lungs and small intestine are particularly rich sources of catalytically-active immunoreactive AmP.
  • guinea pig AmP contains at least three of six blocks of highly conserved sequences characteristic of a recently recognized group of proteins called the proline peptidase family.
  • the match of primary structures appears to have functional significance in that all family members (e.g. human proline dipeptidase) are, like mammalian AmP, capable of hydrolyzing imido (as opposed to amido) bonds.
  • the conserved blocks provided a simple guide for cloning AmP cDNA because one could then specify, in terms of block placements (e.g. block C within the middle of AmP and block F near the C-terminus), pairs of primers that would yield large or small stretches of cDNA.
  • pig kidney cortex AmP has been sequenced almost completely (Edman degradation and some mass spectroscopy) (196).
  • AmP and the entire proline peptidase family have been postulated to be members of a larger protein family ("pita bread-fold" family) not characterized by common functions but by highly similar 3 -dimensional structures.
  • human kidney AmP cDNA was clone.
  • the primers prepared originally to correspond with guinea pig lung AmP sequences worked as well with human kidney mRNA.
  • Blau et al (62) found two boys of consanguineous parents who excreted in urine a mixture of proline-containing oligopeptides, including Gly-Pro, a dipeptide excretory product characteristic of PDP deficiency. However, the boys excreted in greater amounts (up to 30 mg/day) a tetrapeptide, Gly-Pro-Hyp-Gly, not seen in urines of normal subjects nor patients with PDP deficiencies. It was determined that the excreted tetrapeptide has a sequence identical to the N-terminal tetrapeptide of a putative hormone called antiarrhythmic peptide (AAP) (Gly-Pro-Hyp-Gly- Ala-Gly) (51-56).
  • AAP antiarrhythmic peptide
  • AmP occurs in abundance in guinea pig and rat kidneys and lungs but is virtually absent from rabbit and cat kidneys and lungs (16). In fact, human tissues were found to have AmP in relatively high abundance (Table 1). By Northern blot analysis, human kidney, liver, small intestine, heart, lung, colon and placenta are particularly enriched in AmP mRNA (47).
  • This information can be used to a) relate molecular structure to AmP catalytic activity, b) define its cellular and subcellular dispositions so as to clarify orientations of the catalytic site, and c) define the anatomic relationships of AmP to functionally-related "nearest-neighbor" effector and cell signaling molecules.
  • AmP disposed near cell matrix may be well-positioned to participate in secondary, tertiary or higher stages of collagen metabolism
  • AmP disposed on intestinal brush border epithelium likely functions as a specialized digestive enzyme
  • AmP disposed on renal proximal tubule epithelium plausibly participates in conservation of proline
  • AmP in neuronal tissues may process neuropeptides
  • AmP disposed on vascular endothelium processes circulating peptide hormones such as bradykinin (31,34,39, 181).
  • Partial AmP deficiencies may be relatively common, a possibility that has been suggested vis a vis a side effect of angiotensin converting enzyme (ACE) inhibitor therapy (31): ACE inhibitors are widely-used for the treatment of hypertension and congestive heart failure (93). Most patients experience few, if any, side effects. However, a small percentage of patients develop urticaria and angioedema (99), problems that can also occur when bradykinin is infused i.v. in relatively high doses (66). It appears that AmP is normally the last defense against the entry of BK into the systemic arterial blood of patients treated with ACE inhibitors (31). Clearly, patients with a relative or complete AmP deficiency could be at exceptional risk if treated with an ACE inhibitor.
  • ACE angiotensin converting enzyme
  • angioedema affects tissues of the upper airway, thereby obstructing air flow, death can occur within minutes. Therefore, even though angioedema is an uncommon side effect of ACE inhibitors, it would be worthwhile to determine its molecular basis. If an AmP deficiency underlies ACE inhibitor-induced angioedema, a pretreatment test for the deficiency could spare some patients from life-threatening ACE inhibitor-induced angioedema.
  • AmP aminopeptidase P
  • guinea pig serum is a rich source of soluble AmP, which can be purified to obtain two isoforms, Mr 89,000 and 81,500 (22).
  • concanavalin-Sepharose chromatography both isoforms were found to behave as a mixture of biantennary and high mannose glycoproteins (70%/30%).
  • mice were immunized with the biantennary form of guinea pig serum AmP. Both mice produced high titer anti-AmP, which, on Western blotting, proved to be reactive with both AmP isoforms, Mr 89,000 and 81,500.
  • the spleen of one mouse was used to produce hybridomas, twelve of which produced anti- AmP, all of the IgGi isotype.
  • HL510 was used to prepare an immunoaffinity matrix (antibody bound to protein A-Sepharose and then crosslinked with a bifunctional active ester).
  • the immunoaffinity matrix enabled isolated of homogeneous guinea pig AmP in the quantities needed for amino acid sequencing and was used to purify hydrophilic (post-PI-PLC treatment) forms of kidney and lung AmP as well as serum AmP.
  • a 4 ml column of the matrix was used repeatedly to obtain a total of about 20 nmol of apparently pure AmP.
  • coli contain two AmP products and two separate genes (206), which may also be the case for human AmPs. Soluble forms of AmP have also been purified from human platelets (191) and leukocytes (165). Both AmPs migrate on SDS-PAGE at Mr 71,000. On molecular sieving, platelet AmP behaves as a trimer (Mr 223,000) and leukocyte AmP behaves as a dimer (Mr 140,000). No direct studies have been performed to clarify glycosylation, but human platelet AmP was not retained by a mixed concanavalin A/wheat germ lectin chromatography matrix. Sequencing. Guinea pig AmP behaved on Edman degradation as if N-blocked.
  • LysC digests of both kidney and lung AmP were therefore prepared, and the peptide products separated on Tris-tricine gels (79,172). Partial digestion conditions were used to generate relatively large fragments. Separated peptides were blotted to a Problott membrane (ABI), and three lung and four kidney AmP fragments were selected for sequencing. Where overlaps occurred (80 amino acid residues), lung and kidney AmPs were found to be identical in structure.
  • the "BLAST" network (49,50) was used to look for possible similarities to known proteins.
  • the search picked up a tentative match with human proline dipeptidase (PDP).
  • a second search using the "BLOCKS” program (102) revealed that guinea pig AmP contains at least three of six highly conserved blocks of amino acid sequences that define a newly- recognized protein family called the proline peptidase family. Further details on how guinea pig kidney and lung AmPs line up with sequences of known members of the proline peptidase family (of which PDP is a member) were obtained using the program "IALIGN” (77). Through the foregoing analysis, it was evident that guinea pig kidney and lung AmPs contained all of proline peptidase blocks C,E and F.
  • blocks A-F The six conserved blocks in human prolidase (blocks A-F) are arranged alphabetically from the N-terminus.
  • the order of sequenced fragments of guinea pig kidney and lung AmP was deduced.
  • the expected length of protein between the fragments could be estimated, keeping in mind that the number of residues between conserved regions in AmP are not the same as found for other members of the family (blocks E and F are fused in AmP but are separated by more than 20 amino acid residues in PDP) (83,84).
  • This information reduced the number of PCR primers that one would need to test and provided clues for analyzing PCR data.
  • Knowledge of the placement of blocks of conserved sequences also provided clear directions for the use of nested primers.
  • the proline peptidase group is a small family of related proteins including E. coli aminopeptidase P II, E. coli proline dipeptidase and human proline dipeptidase (PDP; prolidase). All three of these proteins are classified as manganese metalloenzymes, primarily because they are stimulated by Mn 2+ . In this regard, mammalian AmP is also stimulated by Mn 2+ in its reaction with some, but not all, substrates (22, 31, 32, 111, 152, 180). Zinc, 0.2 mole, was reported to be present per E.
  • coli AmP subunit as detected by atomic absorption spectrophotometry (206), and pig kidney AmP is reported to contain about 1 mole of Zn per mole of enzyme (108).
  • Finding a match of guinea pig lung AmP with human PDP was intriguing because of their similarity in substrate selectivity.
  • Proline dipeptidase cleaves imide bonds of dipeptides in which proline is C-terminal, whereas AmP acts as an aminoacylproline hydrolase (22,29,32,83,188).
  • Matthews and colleagues solved the three-dimensional structure of E. coli methionine aminopeptidase (AMPM) by x-ray crystallography (59).
  • tuberculosis revealed, in each case, ⁇ sequences characteristic of "pita bread” folds.
  • binding sites for the catalytic divalent metal of AMPM were well-characterized and were known to be disposed on either side of a two- ⁇ - sheet cleft common to AMPM and CREA.
  • Block C clearly is within a ⁇ -sheet of the catalytic crevice and contains two divalent metal ligands (later identified in human kidney AmP as D450 and D451; see below), and blocks E and F are clearly part of an apposing ⁇ -sheet and contain two more metal ligands (E555 and E569 in human AmP).
  • the catalytic metal binding sites could be assigned: block C, D450 and D461; block D, H520; block E, E555; and block F, E569.
  • a putative proton shuttle, H430 could also be postulated.
  • Each of the putative divalent metal-binding ligands and the putative proton shuttle is a reasonable target for preparing site-specific mutants.
  • a sense primer based on QMDCNW (now known to be residues 124- 129 of human AmP) was used with a reverse primer based on FQKEAY (residues 474-479) to obtain a 1068 bp fragment. Fragments from three separate PCR reactions were subcloned (TA Cloning Kit, Invitrogen) and sequenced. All three independent PCR products were found to have identical sequences, ruling out PCR nucleotide-incorporation errors. The remaining 5' and 3' nucleotide sequences were obtained by RACE methods. 5'-RACE was performed using both human kidney and lung poly A RNAs. PCR products were subcloned and sequenced.
  • Kidney and lung cDNA sequences were identical for the N-terminal open reading frame plus 264 bases of the 5 '-untranslated region. 3 '-RACE was performed to obtain the C- terminal portion of AmP coding sequence plus a 1145 base 3 '-untranslated region. Two independent reactions gave identical sequence results.
  • Composite cDNA and amino acid sequences The composite cDNA sequence is shown in SEQ ID NO: 1. The
  • DNA sequence has an open reading frame of 2019 nucleotides.
  • the deduced amino acid sequence (SEQ ID NO: 2) comprises 673 residues with a calculated molecular weight of 75,490.
  • Comparison of the human AmP amino acid sequence to that of the pig shows evolutionary divergence with only 83% amino acid sequence identity between the two species ( Figure 1).
  • Five of six potential N-glycosylation sites found in the pig sequence at residues 34, 48, 64, 277, 290, and 294 are conserved in the human sequence at residues 35, 49, 65, 278, and 291.
  • Five of six cysteine residues that are potentially involved in disulfide bond formation are also conserved.
  • AmP is a GPI-anchored protein
  • the mature protein can be derived from a nascent form containing N- and C- terminal signal peptides that are removed during processing in the endoplasmic reticulum.
  • the N-terminal cleavage site is either Lys-24 or His-22.
  • the most important sequence positions in the von Heijne method are those at -1 and -3. If Lys-24 represents the true cleavage site this would put Pro at the -1 position in the pig sequence which is unusual in eukaryotic signal sequences.
  • Lys-24 and His-22 are both conserved in the human sequence as are the -1 and -3 positions relative to His-22 ( Figure 1).
  • the -3 position relative to Lys-24 is also conserved.
  • the -1 position contains a Thr residue rather than a Pro which is more commonly found in this position in eukaryotic signal sequences.
  • Ala-649 has been predicted to be the C-terminal ⁇ -residue in the pig enzyme with Arg and Ala in the important ⁇ +1 and ⁇ +2 positions, respectively (113).
  • Identical ⁇ , ⁇ +1, and ⁇ +2 residues are found in the human AmP enzyme ( Figure 1).
  • the exact anchorage site can be examined by mutation and by Edman degradation and mass-spectrometry of C-terminal peptides produced by GluC digestion.
  • Genomic DNA Sequence of Human AmP A search of GenBank using the human AmP cDNA sequence revealed a sequence, dJ753P9 (an unfinished human chromosome X genomic sequence from the Sanger Center group of the Human Genome project), containing human AmP sequences. A comparison of this clone with the
  • AmP cDNA sequence revealed segments of the genomic sequence that were in the wrong orientation or relative position, or which were spurious. These errors would not have been readily apparent without comparison to the cDNA sequence.
  • the jumbled dJ753P9 sequence was rearranged to arrive at the genomic sequence of human AmP, including introns.
  • a second sequence, dJ454M7 (a genomic sequence containing the oculocerebrorenal syndrome gene also from the Sanger Center group of the Human Genome project), overlapped the dJ753P9 sequence in the upstream region.
  • sequence data of sequences dJ753P9 and dJ454M7 were produced by the X Chromosome Sequencing Group at the Sanger Centre and can be obtained from ftp ://ftp. sanger. ac.uk/pub/dJ753P9 and ftp ://ftp. sanger. ac.uk/pub/dJ454M7, respectively.
  • SEQ ID NO:3 shows the first 50,000 nucleotides of the AmP genomic DNA (nucleotides 1 to 50,000).
  • SEQ ID NO:4 shows the next 50,000 nucleotides of the AmP genomic DNA (nucleotides 50,001 to 100,000).
  • SEQ ID NO:5 shows the next 44,453 nucleotides of the AmP genomic DNA (nucleotides 100,001 to 144,453).
  • SEQ ID NO:6 shows the next 45,546 nucleotides of the AmP genomic DNA (nucleotides 144,454 to 189,999).
  • SEQ ID NO:7 shows the last 16,955 nucleotides of the AmP genomic DNA (nucleotides 190,000 to 206,954).
  • SEQ ID NOs:3, 4, and 5 represent sequences upstream of the AmP coding region.
  • SEQ ID NO: 6 represents the AmP coding region (including introns) and some downstream sequences.
  • SEQ ID NO: 7 represents sequences downstream of the AmP coding region.
  • the location of introns in the AmP genomic DNA is shown in Table 2. The position refers to the nucleotide positions in SEQ ID NO:6.
  • the coding region in the exonic sequences contain a total of 2019 nucleotides, in perfect agreement with the coding region of human AmP cDNA.
  • the cDNA sequence (SEQ ID NO:l) contains 264 nucleotides of 5' untranslated region, which starts at nucleotide 144,190 in the genomic sequence (nucleotide 44, 190 of SEQ ID NO:5).
  • the 3' untranslated region starts at nucleotide 173,725 in the genomic sequence (nucleotide 29,272 of SEQ ID NO:6).
  • Regulatory sequences are present in the sequences upstream and downstream of the AmP coding sequence.
  • the locations in AmP genomic DNA of restriction sites for rare-cutting restriction enzymes are shown in Table 3. The position refers to the nucleotide positions of the entire genomic sequence (1 to 206,954).
  • carrier APPBz at 2 ⁇ mol/kg completely inhibited hydrolysis of coinjected tracer substrate and can thus be used as a short-acting AmP inhibitor.
  • alternative substrates for AmP should, in saturating doses, also inhibit APPBz- 3 H hydrolysis.
  • BK proved to be an alternative substrate of even higher affinity than carrier APPBz: coinjected BK, at 13 nmol/kg, reduced APPBz- 3 H hydrolysis by half.
  • Des-Arg 9 -BK was an alternative substrate of lesser affinity; ED50 of 107 nmol/kg.
  • Des- Arg 1 -BK is apparently not a substrate for AmP but binds to the catalytic site nonetheless (21,22,31); thus, des-Arg ⁇ BK coinjected with APPBz- 3 H was expected to reduce hydrolysis of the tracer, an expectation met experimentally (ED50 of 30 nmol/kg). Potentiation of effects of bradykinin (BK). If BK inhibits hydrolysis of APPBz- 3 H, BK hydrolysis by AmP should be inhibited by APPBz; a possibility tested as follows: Log dose- response curves were constructed by measuring the mean systemic arterial blood pressure effects of BK injected into the superior vena cava (i.v.) or the root of the aorta (i.a.).
  • the i.v. dose of BK required to reduce arterial blood pressure by, say, 25 mm Hg is 40 or more times the i.a. dose of BK required to exert equivalent effects.
  • saturation of AmP with an inhibitor or alternative substrate should, in effect, potentiate blood pressure effects of i.v. BK. It was found that either of carrier APPBz or des- Arg 9 -BK potentiated blood pressure effects of i.v. BK by up to 4-fold. Effects of i.a.
  • ACE angiotensin converting enzyme
  • Inhibition of ACE potentiates blood pressure effects of i.v. BK by 40- to 200-fold.
  • the four-fold potentiation of i.v. BK effects achieved by inhibition of AmP is less spectacular but, as discussed below, important nonetheless.
  • blood pressure effects of i.v. BK under control conditions and then after administration of a long-acting ACE inhibitor, RAC-X-65 were compared.
  • BK was injected (i.v. and i.a.) alone or BK co-mixed with APPBz at a dose capable of saturating AmP
  • BK is an edematogenic compound capable of inducing urticaria when administered i.v., and has been postulated to play a role in induction of angioedema (99).
  • Human lungs contain ACE, which is distributed so as to have access to circulating substrates such as BK and angiotensin I (66).
  • ACE inhibitors there are now several million patients under treatment with ACE inhibitors and who therefore lack the ability to inactivate BK via the ACE pathway.
  • HL510 and the polyclonal anti-AmP have been used in the immunocytochemistry studies described below. Although the epitope bound by HL510 is not yet known, all data support its specificity. HL510 binds to guinea pig plasma, lung and kidney AmP isoforms and works well for immunoprecipitations, western blots and immunocytochemical studies. HL510 binds rat forms of AmP; thus, parallel studies of the disposition of AmP in guinea pig and rat tissues were conducted. HL510 has anticatalytic effects on human plasma AmP and has proved to be useful for purifying human lung AmP.
  • HL510 reacts specifically with human pulmonary artery, lung microvascular and aortic endothelial cells as evidenced by indirect immunofluorence and immunoprecipitation studies.
  • HL510 immunoaffinity matrix binds the two isoforms (Mr 89,000 and 76,000) of PI-PLC solubilized guinea pig kidney AmP quantitatively.
  • Prolidase a proline peptidase family relative of MW 56,000 (83)
  • ACE pulmonary angiotensin converting enzyme
  • glutaraldehyde fixatives were used, and the light microscopy studies using frozen sections and sections of tissues were fixed in picric acid/paraformaldehyde.
  • the latter fixative is adequate for electron microscope (EM) immunocytochemistry at moderately high resolution (5,6).
  • EM electron microscope
  • Vector ABC kit reagents were used throughout (second antibody bridged via a biotin:avidin complex to horseradish peroxidase), and these too can be used for some EM studies.
  • Micrographs show that AmP immunoreactivity is also disposed on guinea pig renal proximal tubule, jejunum enterocytes and villus vascular cores and in association with microvessels of the endocrine and exocrine pancreas.
  • the kidney micrograph illustrates that cells of the glomerulus, including glomerular endothelium, lack AmP immunoreactivity.
  • Previous studies of ACE were similar: glomerular endothelium was unique among endothelia studied in that it failed to react with anti-ACE (69). Endothelium of small arteries of the renal cortex react with anti-AmP, but by far the greatest AmP immunoreactivity is that of the proximal tubules.
  • Immunofluorescence photographs show the reaction of HL510 with human pulmonary microvascular endothelial cells in culture.
  • Ref 34 contains an immunofluorescence micrograph of the reaction of HL510 with human aorta endothelial cells.
  • Antibodies to AmP can be prepared by using as immunogens unique peptide sequences of human AmP predicted to be antigenic (EGCG program). Further to favor precise localizations, antibodies labeled with colloidal gold particles can be used.
  • EGCG program immunogens unique peptide sequences of human AmP predicted to be antigenic
  • colloidal gold particles can be used as a gpi- anchored enzyme.
  • membrane-bound AmP is expected to be localized in caveolae (137,184). Indeed, the distribution of immuno fluorescent spots in micrographs is typical of antigens situated in caveolae (90,91). AmP and its nearest-neighbors.
  • the orientation of the insert can be verified by a directional PCR reaction, and the correct construct can be used to transfect COS-1 cells.
  • About 2E + 06 cells are plated in 150 cm 2 culture flasks and allowed to proliferate for 24h at 37°C (113). Cells are then washed with Optl-Mem and transfected (5 ⁇ g of DN A/flask) using lipofect Amine. After 2h at 37°C, Dulbecco's modified Eagle's medium containing 10% FCS is added. Twenty four h later, the medium is replaced with fresh, and the cells will be incubated at 37°C for another 24h.
  • Parallel control cultures transfected with vector lacking the AmP cDNA insert, can be processed similarly.
  • a small portion of control and test cells are harvested and examined by indirect immunofluorescence using our monoclonal anti-AmP HL510 as the primary antibody.
  • a second portion of each of the control and test cells are washed free of culture medium and then resuspended in 50 mM Hepes/NaOH buffer, pH 7.4, containing 0.15 M NaCl (assay buffer).
  • the AmP substrate Arg-Pro-Pro-[ 3 H]benzylamide (21) is added to the cell suspension to a final concentration of 20 nM (1 ⁇ Ci/ml).
  • the cell/substrate reaction mixture is incubated at 37°C, and aliquots is collected at timed intervals for measurement of the rate of formation of the expected product, Pro-Pro-[ 3 H]benzylamide (21,22).
  • AmP activity can be computed to yield the first order rate constant, Vmax/Km.
  • COS-1 control cells transfected with vector lacking the AmP cDNA insert
  • the bulk of the COS-1 cells can be worked up to prepare cell membranes.
  • the cells in assay buffer containing 10 ⁇ g/ml of each of pepstatin, leupeptin and aprotinin, are homogenized, and the homogenate is subjected to differential centrifugation (32,110,111).
  • the cell membrane- enriched fraction is assayed for AmP catalytic activity (see above), and then solubilized with 60 mM octyl glucoside (76).
  • Half of the resulting mixture is treated with phosphatidylinositol-specific phospholipase C (recombinant PI- PLC from B. thuringiensis) before phase separation with Triton X-l 14, and the remaining half is directly phase separated.
  • PI-PLC treatment should convert the amphipathic form (partitioned into the Triton phase) into the hydrophilic form. Both amphipathic and hydrophilic forms are subjected to SDS/PAGE under reducing conditions (10% gel). The proteins will be transferred on to Immobilon P for western blot analysis using anti-AmP HL510. Expressed monomeric AmP is expected to have an Mr near 90,000 (22,32,111,152,180). Overexpression of AmP.
  • the baculovirus/Sf9 insect cell system a system known to be capable of expressing biologically functional, glycosylated gpi-anchored proteins, will be used to obtain human kidney AmP in milligram quantities.
  • Recombinant human cluster of differentiation antigen CD59 has been thus obtained in milligram quantities, with not less than 98% of the product bearing the gpi anchor, as judged by Triton X-l 14 phase partitioning before and after treatment with PI-PLC (76).
  • PI-PLC PI-PLC
  • CD59 was produced in three isoforms, all with the expected N-terminal amino acid sequence and all bearing a gpi anchor. Apparently, the glycosylation process was overwhelmed by high protein expression such that the two smaller isoforms were inefficiently glycosylated.
  • the ability of Sf9 cells to N-glycosylate recombinant proteins at expected sites is well-recognized; however, the glycosyl groups are generally of the high mannose type (76). The efficiency of glycosylation improves with increasing time of culture, thus it may be useful to analyze samples, and harvest and replace if indicated, culture medium daily so as to collect separately secreted AmP isoforms that differ in terms of numbers and possibly types of glycosyl groups.
  • glycosyl groups the types of anchors attached to recombinant proteins are characteristic of Sf9 cells and can differ in structure from gpi anchors attached by, e.g., human kidney proximal tubule epithelial cells (76). Nonetheless, Sf9 cell-produced proteins have the expected full-length peptide, correctly folded and crosslinked by disulfide bonds. Recombinant enzymes thus produced are typically fully active (76, 194, 195). Overexpression of wild-type human AmP
  • the cDNA sequence encoding human AmP can be subcloned into the polyhedrin-based plasmid transfer vector pVL1393 (Pharmingen). Recombinant transfer vector can then be cotransfected with Baculogold (Pharmingen) viral DNA into Sf9 insect cells (2 x 10 6 cells in monolayer). Six days after cotransfection, the cells can be harvested and expression of AmP examined by assay of catalytic activity, immunofluorescence and western blotting. Conditioned medium containing recombinant virus is used to reinfect Sf9 cells through 2-3 rounds of amplification to obtain a high titer virus stock (1E+08 virus particles/ml). Optimal conditions of multiplicity of infection and length of infection can be defined.
  • conditioned medium can be harvested and worked up in parallel with the Sf9 cells for their contents of recombinant human AmP.
  • Samples of conditioned medium can be collected at timed intervals before final harvest in order to monitor efficiency of glycosylation.
  • N-glycosylation of AmP early in culture is expected to be relatively inefficient and may provide useful insights if multiple isoforms are obtained at final harvest.
  • Triton X-l 14 phase extractions can be performed to examine for the efficiency of gpi-anchor attachments.
  • recombinant human CD59 it is expected that conditioned medium will contain substantial quantities of recombinant AmP in its amphipathic form (76).
  • amphipathic protein is selected for by Triton X-l 14 phase separation.
  • the Triton phase is collected, diluted and then treated with PI-PLC.
  • the PI-PLC-formed hydrophilic protein expected to be N-glycosylated with high mannose side functions (76), is isolated on concanavalin A-Sepharose. AmP is eluted.
  • the immunoaffinity purification step can then be performed using relatively low protein loads.
  • the goal is to obtain at least 20 nmol (about 2 mg) of pure AmP per 150 cm 2 culture flask.
  • the high titer virus stock produced as described above can be used to scale up production of recombinant AmP as needed. All of the following studies of wild-type AmP can be performed using less than 50 nmol of the pure protein. Characterization of wild-type AmP.
  • kcat, Km and kcat/Km can be measured as described in the studies of guinea pig serum AmP (22). Pure recombinant wild-type human AmP is expected to have a second order rate constant, kcat/Km, on the order of 1.8E + 08 M '1 min '
  • Recombinant AmP can also be tested for thermal stability (152,180), not only for comparison against naturally-occurring AmP, but also to set a baseline for characterizing potentially unstable mutants that lack disulfide bonds, glycosylation sites or metal ligands. Chemical properties. Incorrect estimations of the molar extinction coefficient of angiotensin converting enzyme (ACE) caused confusion for more than a decade, especially in terms of determination of the number of atoms of zinc per molecule of ACE and the specific activity of the pure enzyme (see 27 and its references). To avoid such confusion for AmP, UV spectra (210-340 nm) can be developed using three concentrations of wild-type AmP (optical densities of about 0.2, 0.5 and 1.0 at 280 nm).
  • ACE angiotensin converting enzyme
  • Recombinant AmP (1 nmol in a 1 mm light path cell) can also be characterized by circular dichroism. Spectra can be recorded at 13°C using a AVIV-60DS spectropolarimeter, and, with buffer baseline corrections, relative percentages of ⁇ -helix, ⁇ -sheet, ⁇ -turn and random coil structures can be estimated using AVIV software. The major purpose of these studies is to establish a basis for detecting variations in higher structure of unstable or catalytically-inactive mutants. Recombinant AmP can be analyzed by MALDI-TOF mass spectrometry to weigh the parent molecule and any dimer or trimer forms, and examine for characteristic fragmentation patterns that may later be useful for analyzing mutants (36, 196).
  • O-glycosidase can be used to rule in or out the presence of O-linked carbohydrate (196).
  • the following text assumes that AmP does not contain O-linked carbohydrate, and the approach will require adjustments along obvious lines if the assumption is incorrect.
  • O-glycosylation seems unlikely in that exhaustive treatment of pig AmP (PI-PLC solubilized) with N-glycosidase F yields a peptide of Mr 71,000, essentially as expected for a 626 residue peptide plus a gpi-anchor remnant (196).
  • D157-P158 Human kidney AmP contains a single Asp-Pro bond (D157-P158) (see SEQ ID NO:2) that is expected to hydro lyze spontaneously under the acid conditions required to form CNBr or BNPS skatole fragments (75,126). Since its spontaneous hydrolysis could complicate early efforts to interpret peptide fragment fingerprints, hydrolysis of AmP at D157-P158 should be attempted before beginning conventional fingerprinting. As described below, several analytical advantages accrue if the D-P bond can be hydrolyzed efficiently.
  • Recombinant AmP 0.1 nmol initially, is dissolved in 1 ml of 7M guanidinium chloride in 10% acetic acid adjusted to pH 2.5 with pyridine (126). The mixture is incubated at 37°C for up to 96h. At timed intervals, samples are examined by mass spectrometry and N-sequenced; the latter to monitor the rate of appearance of the new N-terminus, PFLL (residues 158- 161). For the following, it is assumed for convenient discussion that K24 (probably acylated) is the first residue of mature AmP and that A649 is the last. Elsewhere, these assumptions can be tested.
  • the expected two pieces should be readily separated on Sephadex G-50. If reduction is required for separation of the N- and C-pieces, this will be evidence for the presence of a disulfide bond.
  • the N-piece contains three potential N-glycosylation sites, N35, N49 and N65, and two Cys residues, C36 and C127.
  • the N-piece is expected to have an N- ⁇ acyl modification (22, 111,180).
  • the N-piece is resistant to Edman degradation, it can be digested with AspN to obtain a 43 amino acid (a.a.) residue peptide which contains C36 and potential glycosylation sites N35, N49 and N65.
  • K24 is the N-terminal residue of mature AmP, an acylated (possibly diacylated) tripeptide is expected, and its mass should reveal the identity of the acyl-function (125, 154, 189). If one or more of its glycosylation sites is glycosylated, the 43 residue peptide can be separated from the remainder of the AspN digest using con A-Sepharose (see above).
  • N65 Given its distance from the AspN-generated N-terminus, N65 can be made more effectively accessible to Edman sequencing by cleavage of the M61-Q62 bond with CNBr (41 ,48,49,75).
  • the expected peptide, Q62-T74 can be weighed by mass spectrometry to determine whether N65 is or is not glycosylated (36).
  • peptides of special interest e.g. the AspN-generated N-terminal acyl-tripeptide
  • reverse phase HPLC Brownnlee, aquapore 300
  • a morpholine phosphate buffer, pH 6.5 as the mobile phase can be used (103). This system provides high resolution under conditions unlikely to damage the expected gpi-tail piece and unlikely to hydrolyze peptide bonds artifactually.
  • T245-E285 and T286-E303 are isolated on con A-Sepharose, mass spectrometry can be used to verify that each of N278 and N291 is glycosylated. Edman degradation of T286-E303 may reveal whether C294 and C299 are, or are not, linked by a disulfide bond.
  • GluC digestion of the C-piece is expected to generate a relatively small C-terminal peptide, the last residue of which, in native AmP, is attached, via ethanolamine, to the gpi anchor (86,139-141,144,159,162). If GluC can hydrolyze an E-P bond, the C-terminal peptide is expected to be PLAA. If not, the GluC-generated C-terminal peptide is expected to be W639-A649. It should be possible to collect either peptide by immunoprecipitation.
  • the PI-PLC-generated hydrophilic form of AmP is known to possess a C-terminal common recognition determinant (CRD) (29,32, 111,113,180).
  • PI-PLC cleaves the phosphodiester bond between inositol and the diacylglycerol, forming a 1,2-cyclic phosphate ring on the inositol residue.
  • the cyclic inositol phosphate is highly immunogenic, and antibodies prepared against any PI-PLC-solubilized protein cross-react with this epitope (the cross-reacting determinant, CRD) (86, 139, 140,208).
  • CRD cross-reacting determinant
  • AmP (not previously exposed to strong acid) can be digested, in a separate experiment, with GluC and then isolate the CRD-bearing peptide as described above. Focus on cysteine residues.
  • the foregoing chemical analysis will make it clear which of the potential N-glycosylation sites of wild-type recombinant AmP are in fact glycosylated.
  • some clues may be gained on the presence and dispositions of disulfide bonds.
  • unequivocal assignments of Cys residues taken up in disulfide bonding will require an independent approach, such as the following.
  • Native recombinant AmP 1 nmol, in 50 mM Hepes/NaOH buffer, pH 8.3 (21,22), can be reacted with 1,000 nmol of (l- 14 C)iodoacetamide, ⁇ 3 Ci/mol, at 25°C for lh.
  • Excess 14 C-iodoacetamide is removed by centrifugal ultrafiltration (10K NMWL) with washing. Specific radioactivity can be measured by liquid scintillation counting to estimate the number of alkylated C residues.
  • the 14 C-labeled protein product can then be acid-treated to hydrolyze the D157-P158 bond (see above) and recover the N- and C-pieces (respectively, K24-D157 and P158-A649).
  • the N- and C-pieces (with or without a reducing agent) are separated, and their specific radioactivities measured.
  • the N-piece can be digested with AspN to yield the 43 residue peptide that contains C36 and a 44 residue peptide that contains C127.
  • the former peptide expected to be glycosylated, is separated from the latter on con A-Sepharose column chromatography. Each of the separated peptides can be assayed for its C- content. If the N-piece is itself not labeled with 14 C, AspN digestion and subsequent studies will not be necessary.
  • the focus should be on GluC-digest peptides containing residues C294 and C299 (peptide T286-E303) and C531 (peptide A505-E534).
  • T286-E303 if glycosylated at N291, should be easily separated on con A-Sepharose from A505-E534. If not, the 18 residue peptide should be readily separated from the 30 residue peptide by reverse phase HPLC. The separated peptides can be assayed for their contents of 14 C. Near-neighbor C residue pairs are often linked by disulfide bonds (185).
  • peptide T286-E303 may be unlabeled.
  • C531 will be labeled with 14 C.
  • a parallel experiment can be conducted in which native AmP, saturated with bradykinin (BK) (50 ⁇ M; Ki 1.1 ⁇ M (22,113)), is reacted with 14 C-iodoacetamide as above.
  • AmP is not a thiol protease and is not inhibited by iodoacetamide nor N-ethylmaleimide. However, it is partially (-70%) inhibited by p-hydroxy-mercuribenzoate, even with the latter at low concentration (-10 nM) (21,22,111,180).
  • C531 is situated more or less in the middle of the putative catalytic metal ligands, D450, D461, H520, E555 and E569, it is highly plausible that p-hydroxymercuribenzoate binds to C531 and sterically hinders substrate binding and/or interferes with appropriate ligation of catalytic metal to the peptide backbone.
  • p-hydroxymercuribenzoate binds to C531 and sterically hinders substrate binding and/or interferes with appropriate ligation of catalytic metal to the peptide backbone.
  • alkylation of C531 by 14 C- iodoacetamide should be prevented or strongly inhibited.
  • a third experiment can be performed in which native AmP is reacted with 14 C-iodoacetamide as in the first experiment. After lh at 25°C, excess 14 C-iodoacetamide is removed and then the 14 C-labeled AmP is denatured and reduced (185). The reduced peptide is treated with vinylpyridine. The subsequent work up can proceed as in the first experiment to obtain AspN peptides of the N-piece and GluC peptides of the C-piece (pieces produced by acid hydrolysis of D157-P158). The relevant peptides can then be N- sequenced to determine which C residues were alkylated with iodoacetamide and which, after reduction, were covalently-bound to vinylpyridine.
  • the disulfides are most likely to link C36 ⁇ C127 and C294- C299. If more than one Cys is in reduced form, there cannot be fewer than three reduced Cys residues, in which case there cannot be more than one disulfide bond. In the latter scenario, the two disulfide-linked Cys residues can be identified as their vinylpyridine derivatives.
  • Sturrock et al (185) have recently detailed a MALDI-TOF mass spectrometry approach for locating disulfide bonds which we plan to use if our simpler plans yield equivocal results.
  • Dr. Nancy D. Denslow has recently developed a procedure in which a target protein is hydrolyzed by reacting reduced Cys residues with DTNB (36).
  • C36 immediately follows an N-glycosylation site, N35, and may, if in reduced form, be sterically-hindered and inaccessible to 14 C- iodoacetamide, this anomalous behavior can be clarified, if encountered, by reacting AmP with N-glycanase before treatment with 14 C-iodoacetamide.
  • N35 N-glycosylation site
  • the baculovirus/Sf9 expression system can also be used to produce mutant forms of AmP.
  • the mutants are selected to help clarify catalytic function in terms of roles of the putative protein shuttle, H430, and putative catalytic metal ligands, D450, D461, H520, E555 and E569.
  • Mutant proteins will then be expressed in the baculovirus/Sf9 insect cell system under the conditions established for expression of the wild-type enzyme. The cells themselves will be examined by catalytic assay and immunofluorescence. Mutant proteins will be purified and analyzed as described above for wild-type AmP. All mutants will be characterized by mass spectrometry, UV spectrometry, circular dichroism, quantitative amino acid analysis and fingerprinting of peptide fragments (mass spectrometry and SDS-PAGE with and without a reducing agent).
  • Catalytically-active mutants will be characterized to measure kcat, Km and kcat/Km using Arg-Pro-Pro-[ 3 H]benzylamide, bradykinin and Gly-Pro-Hyp as substrates (22,113,180). Temperature and pH stabilities will be defined (180).
  • the first mutant to be prepared is one in which the putative proton shuttle, H430, is replaced with F. If H430 is in fact the proton shuttle, the F430 mutant is expected to be essentially inactive.
  • Pig kidney AmP is completely inactivated by diethylpyrocarbonate in a concentration that derivatizes two H residues per molecule of AmP (134). Activity is restored by treatment of the derivatized AmP with hydroxylamine. It is plausible that H430 is accessible to diethylpyrocarbonate.
  • the second mutant to be prepared is that in which the putative catalytic metal ligand H520 (also likely to be accessible to diethylpyrocarbonate) is replaced with F.
  • H520 also likely to be accessible to diethylpyrocarbonate
  • Five mutants will be prepared: N35 ⁇ Q, N49 ⁇ Q, N65 ⁇ Q, N278->Q and N291 ⁇ Q.
  • Our objective here is to determine whether glycosyl groups indirectly support catalytic activity, perhaps in terms of maintaining structure, stability and solubility. Should the glycosyl groups effect catalytic function little or not at all, it may be feasible in a future grant period to obtain a catalytically-active "deglycosylated" AmP amenable to x-
  • C ⁇ S mutants C36, C127, C294, C299 and C531. Characterization of these mutants should reveal roles of disulfide bonds in maintaining higher structure.
  • C531—»S mutant may help clarify the anomalous partial inhibition of wild-type AmP by p- hydroxymercuribenzoate (pHMB):
  • pHMB p- hydroxymercuribenzoate
  • the S531 mutant is expected to be catalytically-active and resistant to inhibition by pHMB.
  • AmP is selective, but not specific, in terms of substrate hydrolysis. In these terms, anatomical distribution can be understood to restrict access of AmP to those substrates available in the cellular or extracellular compartment in which the catalytic site is disposed.
  • AmP disposed on small intestine brush border epithelium could plausibly function as a digestive enzyme that facilitates breakdown of collagenous foodstuffs
  • AmP disposed on renal proximal tubule epithelium may function to process filtered peptides so as to conserve amino acids and modulate effects of some peptide hormones.
  • the first objective is to determine by immunocytochemistry at the level of electron microscopy anatomical dispositions of AmP and orientation of its catalytic site.
  • anatomical disposition of a given protein can be a determinant of secondary or tertiary reactions conducted by "near- neighbor" molecules, a concept well-recognized in terms of receptors and coupled signaling proteins.
  • the second objective is to help define morphologically "near-neighbors" of AmP whose functions may reasonably be influenced by reactions catalyzed by AmP. Preparation of antibodies.
  • Monoclonal antibody HL510 prepared against guinea pig serum AmP (22,32), is reactive with human AmP and has been used in immunofluorescence studies to localize AmP on human endothelial cells (34).
  • HL510 for immunocytochemistry; however, one will in parallel prepare antibodies against specific peptide sequences in human kidney AmP that are predicted to be highly antigenic.
  • EGCG program Wellcome Trust Genome
  • the goal is to obtain at least one high affinity antiserum to a known epitope that does not occur in other proteins of the "pita bread" family of proteins (59).
  • AmP peptide E285-W323, which contains one potential N- glycosylation site and two C residues that may be disulfide-linked, will be the first tested.
  • the 39-amino acid residue peptide will be synthesized by the University of Florida peptide synthesis facility.
  • the free peptide and the peptide coupled to polylysine will be used as immunogens.
  • the monoclonal antibody facility will immunize five mice with each immunogen.
  • Antibody titers will be measured by ELISA. Typically, one of a group of five mice is superior in terms of antibody response (titer and affinity) and provides a basis for choosing which mouse to use for preparing hybridomas.
  • Antibody isotype will be determined, and octyl glucoside-treated homogenate of human kidney cortex (from the National Disease Research Interchange/Human Biological Data Interchange, NDRI) will be used for SDS-PAGE and western blotting. The homogenate will also be used for protein A-Sepharose immunoprecipitation of AmP. Part of the immunoprecipitate will be denatured and subjected to SDS-PAGE to examine for the expected Mr 90,000 protein. The remainder will be packed into a small column and then washed with 0.1 M ethanolamine to separate native AmP from antibody (113). The eluted protein will be examined for AmP catalytic activity using Arg-Pro-Pro-[ 3 H]benzylamide as substrate (21).
  • the goal is to obtain a specific antibody capable of binding human AmP at an affinity sufficiently high to enable immunocytochemistry studies and immunoaffinity purifications of native AmP from a range of human tissue sources.
  • the immediate work plan focuses largely on determining cellular and subcellular dispositions of AmP. Longer term, the antibodies to AmP will be useful for other purposes such as epidemiologic surveys for AmP deficiency states (62).
  • the first immunogen, E285-W323 contains a tyrosine residue and could therefore be readily labeled with 125 I for development of a competitive radioimmunoassay for AmP.
  • the first peptide immunogen fails to yield an antibody capable of immunoprecipitating native human AmP, one will prepare alternative antigenic sequences; in order of predicted high scores: T38-T51, P582-R597 and (if needed) L568-K578.
  • Antibodies will be purified on DE-52 cellulose (5,6). As necessary, specific anti-AmP will be immunoabsorbed on antigen covalently bound on Sepharose or the original peptide synthesis resin and then eluted with 0.1 M ethanolamine (32,113). Initially, one will use second antibody conjugates for immunocytochemical studies. However, it has been argued that crosslinking of primary antibodies by second antibodies may cause cell membrane antigens to move into caveolae (143,145,153). If the subcellular localization AmP appears to be influenced by second antibody, one will conjugate AmP directly.
  • Antibodies to human AmP antigenic amino acid sequences will be prepared for final studies. Initially, one will use second antibody conjugates as markers (conjugates of rabbit anti-mouse IgGi and, separately, goat anti-mouse IgGi). The second antibodies will be labeled with colloidal gold (5 or 20 nm) (Goldmark), and reacted tissues will then be prepared for EM as one have described elsewhere (5,6). Alternatively, primary antibodies labeled with 5 or 20 nm colloidal gold can be used.
  • Negative controls will include omission of anti-AmP and substitution of the specific antibody with mouse IgG t anti-theophylline (the latter irrelevant antibody to examine for Fc receptors). Anti-AmP previously saturated with AmP will also be used. Positive controls will include use, as the first antibody, monoclonal mouse anti-ACE (an IgM) and polyclonal rabbit anti-fibronectin (30). The positive control studies will provide a basis for comparison of the disposition(s) of AmP with a marker known to occur on the luminal surface of endothelium (ACE) and with a marker known to be disposed in large part in the extracellular matrix (fibronectin). AmP is believed to be disposed in part on the endothelial surface (31,34,39,44,46).
  • AmP is believed to be among the enzymes that degrade collagen fragments produced by collagenase (165,204,205); thus, some AmP may be disposed near collagen matrix.
  • second antibodies e.g., rabbit anti- mouse IgGt-Snm colloidal gold for AmP and goat anti-rabbit IgG-20 nm colloidal gold (Zymed) for fibronectin.
  • monoclonal anti- ACE one have a polyclonal rabbit anti-ACE that will be used similarly for the co-localizations of AmP and ACE.
  • Our mouse anti-guinea pig AmP binds human AmP (32), but at relatively low affinity.
  • the polyclonal mouse anti-human AmP is expected to have a much higher affinity, and one or more of the monoclonal antibodies may as well.
  • Immunocytochemical localizations of AmP will use human tissues (from NDRI); kidney, small intestine, liver, heart, lymphocytes, platelets, bone marrow and lungs fresh-fixed in picric acid/paraformaldehyde.
  • Clonetics also supplies human renal proximal tubule epithelial cells and endothelial cells from aorta, pulmonary artery and lung microvasculature, all of which one will use for comparison studies.
  • Cells in culture provide special opportunities for EM immunocytochemistry.
  • cells in monolayer culture can be examined in cross section and as whole cell mounts (10).
  • calmodulin is disposed in endothelial caveolae.
  • high voltage EM of permeabilized whole endothelial cells viewed on face calmodulin was found disposed in tracts of caveolae, along microfiloments and in cleavage furrows of dividing cells.
  • renal proximal tubule epithelial and vascular endothelial cells in culture one can localize AmP bound to cell membrane and/or disposed in intracellular compartments.
  • AmP appears by light microscopy (39) to be disposed on brush border epithelium and endothelium of the villus vascular core of the small intestine. Lung tissue will be examined next, as described above. Separately, fixed cultures of endothelial cells from aorta, pulmonary artery and lung microvasculature (all from Clonetics) will be examined, intact and permeabilized. Soluble forms of AmP.
  • the sense and antisense primers will be selected to cover sequence from just upstream of the putative proton shuttle (H430) to a downstream site just 3' to the last putative metal ligand (E569).
  • the PCR product if obtained, will be sequenced. If, in fact, lymphocyte and adrenal medulla AmPs are encoded over their putative "pita bread" domains as is kidney AmP, one will (as described above) examine by 3 'RACE RT-PCR for alternative C-terminal sequences that may direct soluble AmPs to intracellular sites.
  • Gpi-anchored T-cell receptor is coupled to Src-family kinases (142).
  • Src-family kinases 142
  • IPG inositol phosphoglycan
  • Purified IPGs alone can mimic insulin activities. Through the same, or a parallel pathway, insulin stimulates a tyrosine phosphorylation of caveolin (142).
  • bradykinin in concentrations as low as 10 pM, causes endothelial cells to mobilize arachidonate, some of which is converted into thromboxane A 2 (8-11).
  • Des-Arg ⁇ BK the product formed by AmP, is the only lower homolog of BK, in a near-comparable concentration, capable of mobilizing endothelial arachidonate. Possibly of relevance, des-Arg ⁇ BK has as great an affinity for AmP as BK itself.
  • a gpi- anchor at issue is that of AmP, and part or all of the arachidonate mobilized comes from the diacylglycerol formed by gpi-anchor hydrolysis.
  • BK may exert some of its effects via AmP.
  • endothelial AmP is largely restricted to caveolae, it is well-positioned for at least indirect linkage with eNOS and guanylate cyclase, which appear to be largely disposed on the cytoplasmic aspect of caveolae (92,131). Endothelial cells respond to BK as if they have B2 receptors; however the subcellular dispositions of B2 receptors have, to our knowledge, never been defined at the level of electron microscopy.
  • B2 receptor If, in fact, binding of BK to the B2 receptor activates eNOS and guanylate cyclase (as opposed to binding of BK to an alternative effector), the B2 receptor is likely in very close physical proximity.
  • Our immediate objective here is to develop a novel perspective on how BK exerts effects on endothelium by helping to define nearest-neighbors of AmP and the B2 receptors.
  • Such data as are available indicate that the B2 receptor is situated on or within a cell membrane microdomain, perhaps in caveolae, that can be rapidly taken up by endocytosis (63).
  • endothelial cell plasma membrane/caveolae fractions prepared as described previously (3,4,8,11).
  • post- confluent endothelial cells in culture which contain caveolae in large numbers (7,8,10,11)
  • 5'-adenosine monophosphate 5'-AMP
  • Caveolar 5'-AMPase a gpi-anchored protein, hydrolyzes 5'- AMP to form adenosine and Pi.
  • Pi is precipitated as lead phosphate within caveolae and thereby greatly increases the density of the plasma membrane/caveolae fraction.
  • the latter fraction is then easily separated from soluble proteins and other membrane systems by low g-force ( ⁇ 100xg) centrifugation of the reaction mixture through a relatively dense sucrose cushion (4).
  • g-force ⁇ 100xg
  • sucrose cushion (4) Remarkably, about 65% of the 5'-AMPase remains active, and angiotensin converting enzyme (3,4) and AmP activities (unpublished) are readily measured.
  • the resulting endothelial cell membrane/caveolae "ghosts" provide a number of advantages for our present purposes. Firstly, antigenic sites on both the extracellular and cytoplasmic aspects of the cell membrane are accessible to added antibodies. Secondly, the fraction contains both
  • the plasma membrane/caveolae fraction can be treated with Triton X-l 00 to form its Triton-soluble and Triton-insoluble subfractions (150,175). AmP and 5'- AMPase are expected to be enriched in the Triton-insoluble particulate.
  • One or more of the serines of C361-Q395 is phosphorylated when the B2 receptor of human foreskin fibroblasts is reacted with BK (63).
  • mouse anti-AmP and rabbit anti-B2 receptor preparations one can localize the target antigens on human endothelial cell (Clonetics) plasma membrane/caveolae fractions using anti-mouse IgG conjugated to 5 nm colloidal gold and anti-rabbit IgG conjugated to 20 nm colloidal gold.
  • our approach should also help clarify anatomic associations between proteins disposed on the extracellular aspect of the plasma membrane with functionally-linked counterparts disposed on the cytoplasmic aspect.
  • Success in this subproject can be exploited by us and others in terms of relating morphologically a host of other proteins of interest, including (but not limited to) the caveolins, Ca 2+ -ATPase, the IP 3 receptor, adenosine and prostaglandin transporters and heterotrimeric G proteins (90,130,132,137,173,184).
  • RNA clones encoding human membrane-bound AmP were isolated by reverse transcription-polymerase chain reaction (RT- PCR) of human kidney and lung poly(A)+ RNA.
  • RT- PCR reverse transcription-polymerase chain reaction
  • Northern hybridization analysis and RT-PCR suggests that the soluble and membrane-bound forms of human AmP are products of two distinct mRNAs which may be produced through alternative splicing, have different C-terminal sequences.
  • Intronic sequences involved in such alternative splicing can be included in human AmP constructs to allow production of both forms of human AmP. In such constructs, it is preferred that sequences from only the specific introns involved in the alternative splicing be used.
  • Such a construct is thus a cDNA/genomic hybrid construct, containing both cDNA and genomic DNA. The cDNA portion of such a construct lacks intronic sequences which are present in corresponding genomic sequences. Construction of Transgenic Animals. Animal Sources.
  • mice suitable for transgenic experiments can be obtained from standard commercial sources such as Charles River (Wilmington, MA), Taconic (Germantown, NY), and Harlan Sprague Dawley (Indianapolis, IN). Many strains are suitable, but Swiss Webster (Taconic) female mice are preferred for embryo retrieval and transfer. B6D2F ! (Taconic) males can be used for mating and vasectomized Swiss Webster studs can be used to stimulate pseudopregnancy. Vasectomized mice and rats can be obtained from the supplier.
  • mice Six weeks of age are induced to superovulate with a 5 IU injection (0.1 cc, ip) of pregnant mare serum gonadotropin (PMSG; Sigma) followed 48 hours later by a 5 IU injection (0.1 cc, ip) of human chorionic gonadotropin (hCG; Sigma). Females are placed with males immediately after hCG injection.
  • PMSG pregnant mare serum gonadotropin
  • hCG human chorionic gonadotropin
  • Embryos can be implanted at the two cell stage.
  • Randomly cycling adult female mice are paired with vasectomized males. Swiss Webster or other comparable strains can be used for this purpose.
  • Recipient females are mated at the same time as donor females.
  • the recipient females are anesthetized with an intraperitoneal injection of 0.015 ml of 2.5% avertin per gram of body weight.
  • the oviducts are exposed by a single midline dorsal incision. An incision is then made through the body wall directly over the oviduct. The ovarian bursa is then torn with watchmakers forceps.
  • Embryos to be transferred are placed in DPBS (Dulbecco's phosphate buffered saline) and in the tip of a transfer pipet (about 10 to 12 embryos). The pipet tip is inserted into the infundibulum and the embryos transferred. After the transfer, the incision is closed by two sutures.
  • Transgenic Rats The procedure for generating transgenic rats is similar to that of mice (Hammer et al, Cell 63 : 1099-112 (1990)). Thirty day-old female rats are given a subcutaneous injection of 20 IU of PMSG (0.1 cc) and 48 hours later each female placed with a proven male.
  • the live embryos are moved to DPBS for transfer into foster mothers.
  • the foster mothers are anesthetized with ketamine (40 mg/kg, ip) and xylazine (5 mg/kg, ip).
  • a dorsal midline incision is made through the skin and the ovary and oviduct are exposed by an incision through the muscle layer directly over the ovary.
  • the ovarian bursa is torn, the embryos are picked up into the transfer pipet, and the tip of the transfer pipet is inserted into the infundibulum. Approximately 10 to 12 embryos are transferred into each rat oviduct through the infundibulum. The incision is then closed with sutures, and the foster mothers are housed singly.
  • Embryonic Stem (ES) Cell Methods Introduction of DNA into ES cells. Methods for the culturing of ES cells and the subsequent production of transgenic animals, the introduction of DNA into ES cells by a variety of methods such as electroporation, calcium phosphate/DNA precipitation, and direct injection are described in detail in Teratocarcinomas and Embryonic Stem Cells, A Practical Approach, ed. E.J. Robertson, (IRL Press 1987), the teachings of which are incorporated herein. Selection of the desired clone of transgene-containing ES cells can be accomplished through one of several means. For random gene integration, an AmP clone is co-precipitated with a gene encoding neomycin resistance.
  • Transfection is carried out by one of several methods described in detail in Lovell-Badge, in Teratocarcinomas and Embryonic Stem Cells, A Practical Approach, ed. E.J. Robertson, (IRL Press 1987), or in Potter et al, Proc. Natl. Acad. Sci. USA 81 :7161 (1984).
  • Lipofection can be performed using reagents such as provided in commercially available kits, for example DOTAP (Boehringer-Mannheim) or lipofectin (BRL). Calcium phosphate/DNA precipitation, lipofection, direct injection, and electroporation are the preferred methods.
  • 0.5 X 10 6 ES cells are plated into tissue culture dishes and transfected with a mixture of the linearized AmP clone and 1 mg of pSV2neo DNA (Southern and Berg, J. Moi. Appl. Gen. 1 :327-341 (1982)) precipitated in the presence of 50 mg lipofectin (BRL) in a final volume of 100 ⁇ l.
  • the cells are fed with selection medium containing 10% fetal bovine serum in DMEM supplemented with G418 (between 200 and 500 ⁇ g/ml). Colonies of cells resistant to G418 are isolated using cloning rings and expanded. DNA is extracted from drug resistant clones and Southern blots using an AmP cDNA probe can be used to identify those clones carrying the AmP sequences. PCR detection methods may also used to identify the clones of interest.
  • DNA molecules introduced into ES cells can also be integrated into the chromosome through the process of homologous recombination, described by Capecchi (1989). Direct injection results in a high efficiency of integration. Desired clones can be identified through PCR of DNA prepared from pools of injected ES cells. Positive cells within the pools can be identified by PCR subsequent to cell cloning (Zimmer and Gruss, Nature 338: 150-153 (1989). DNA introduction by electroporation is less efficient and requires a selection step.
  • Naturally cycling or superovulated female mice mated with males can be used to harvest embryos for the implantation of ES cells. It is desirable to use the C57BL/6 strain for this purpose when using mice. Embryos of the appropriate age are recovered approximately 3.5 days after successful mating. Mated females are sacrificed by CO 2 asphyxiation or cervical dislocation and embryos are flushed from excised uterine horns and placed in Dulbecco's modified essential medium plus 10% calf serum for injection with ES cells. Approximately 10 to 20 ES cells are injected into blastocysts using a glass microneedle with an internal diameter of approximately 20 ⁇ m.
  • Embryos to Pseudopregnant Females. Randomly cycling adult female mice are paired with vasectomized males. Mouse strains such as Swiss Webster, ICR or others can be used for this purpose. Recipient females are mated such that they will be at 2.5 to 3.5 days post-mating when required for implantation with blastocysts containing ES cells. At the time of embryo transfer, the recipient females are anesthetized with an intraperitoneal injection of 0.015 ml of 2.5% avertin per gram of body weight. The ovaries are exposed by making an incision in the body wall directly over the oviduct and the ovary and uterus are externalized.
  • Transgenic rodents can be identified by analyzing their DNA. For this purpose, tail samples (1 to 2 cm) can be removed from three week old animals. DNA from these or other samples can then be prepared and analyzed by Southern blot, PCR, or slot blot to detect transgenic founder (F 0 ) animals and their progeny (F] and F 2 ).
  • nucleic acid molecule encoding the amino acid sequence shown in SEQ ID NO:2, or a fragment of at least six amino acids of the amino acid sequence shown in SEQ ID NO:2.
  • the nucleic acid molecule includes expression sequences, at least one intron, or both.
  • Preferred forms of the nucleic acid molecule are SEQ ID NO:l, SEQ ID NO:6, and nucleotides 1 to 29,271 of SEQ ID NO:6.
  • the fragments contain at least 10 nucleotides, at least 15 nucleotides, at least 18 nucleotide, or at least 20 nucleotides.
  • aminopeptidase P regulatory sequences present SEQ ID NOs:3, 4, 5, 6, and 7.
  • a preferred regulatory sequence is a fragment of SEQ ID NO: 5 that promotes transcription of a nucleic acid segment operatively linked to the fragment.
  • proteins having the amino acid sequence shown in SEQ ID NO:2 or a variant amino acid sequence where one or more amino acids shown in SEQ ID NO: 2 are replaced with a conservative substitute amino acid A preferred form of the protein has from one to ten amino acids shown in SEQ ID NO:2 are replaced with a conservative substitute amino acid.
  • proteins including a portion of the amino acid sequence shown in SEQ ID NO: 2 such that the protein is soluble in aqueous solution also referred to as soluble aminopeptidase P.
  • antibodies reactive with the disclosed proteins or peptides are also disclosed.
  • Also disclosed is a method of detecting aminopeptidase P mutants performed by comparing all or a part of a nucleotide sequence encoding aminopeptidase P with the corresponding nucleotide sequence of SEQ ID NO: 1, or the collective nucleotide sequence represented by SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, and SEQ ID NO:7. Also disclosed is a method of identifying a compound that inhibits aminopeptidase P by bringing into contact cells and a compound to be tested, measuring the level of aminopeptidase P activity in the cells, and comparing the measured level of activity with the level of activity in cells not brought into contact with the compound to be tested.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne l'ADNc et l'ADN génomique de l'aminopeptidase P humaine. L'invention concerne également la protéine de l'aminopeptidase P humaine et des anticorps réagissant à l'aminopeptidase P humaine. Ces molécules, et leurs dérivés, sont utiles pour les analyses visant à détecter des polymorphismes, des variants protéiniques, et l'activité de l'aminopeptidase, et à identifier des composés inhibant l'expression des gènes d'aminopeptidase et l'activité de la protéine aminopeptidase.
PCT/US1998/018426 1997-09-02 1998-09-02 Gene d'aminopeptidase p humaine WO1999011799A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU93034/98A AU9303498A (en) 1997-09-02 1998-09-02 Human aminopeptidase p gene

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5785497P 1997-09-02 1997-09-02
US60/057,854 1997-09-02

Publications (2)

Publication Number Publication Date
WO1999011799A2 true WO1999011799A2 (fr) 1999-03-11
WO1999011799A3 WO1999011799A3 (fr) 1999-05-27

Family

ID=22013133

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/018426 WO1999011799A2 (fr) 1997-09-02 1998-09-02 Gene d'aminopeptidase p humaine

Country Status (3)

Country Link
US (1) US6399349B1 (fr)
AU (1) AU9303498A (fr)
WO (1) WO1999011799A2 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001000811A3 (fr) * 1999-06-30 2001-03-22 Millennium Pharm Inc Nouvelle aminopeptidase humaine (17867)
WO2001059134A1 (fr) * 2000-02-11 2001-08-16 Lexicon Genetics Incorporated Proteases humaines et polynucleotides codant pour elles
WO2002061131A3 (fr) * 2000-12-04 2003-06-19 Bristol Myers Squibb Co Polymorphismes de nucleotides simples humains
WO2004104595A2 (fr) * 2003-05-22 2004-12-02 Bayer Healthcare Ag Agents diagnostiques et therapeutiques destines a des maladies associees a la x-pro dipeptidase (pepd)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7232889B2 (en) 1999-03-08 2007-06-19 Genentech, Inc. PRO300 antibodies
WO2002059343A2 (fr) * 2000-10-31 2002-08-01 Vanderbilt University Marqueurs biologiques et tests diagnostiques pour oedeme angioneurotique associe a un inhibiteur de l'enzyme de conversion de l'angiotensine et a un inhibiteur de la vasopeptidase
US7273718B1 (en) 2002-06-07 2007-09-25 Ryogen Llc Isolated genomic polynucleotide fragments from chromosome 10q25.3 that encode human soluble aminopeptidase P
WO2004104575A2 (fr) * 2003-05-23 2004-12-02 Bayer Healthcare Ag Agents diagnostiques et therapeutiques destines a des maladies associees a x-prolyl aminopeptidase 2 (xpnpep2)
US7252850B2 (en) * 2003-05-30 2007-08-07 Delavau Llc High protein and high fiber food products
US7109015B2 (en) * 2004-03-29 2006-09-19 Academia Sinica Removal of N-terminal methionine from proteins by engineered methionine aminopeptidase

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5234811A (en) * 1991-09-27 1993-08-10 The Scripps Research Institute Assay for a new gaucher disease mutation
WO1993004171A1 (fr) * 1991-08-19 1993-03-04 Symbicom Aktiebolag Beta-caseine humaine, procede de preparation et utilisation
US6319687B1 (en) * 1992-09-24 2001-11-20 The United States Of America As Represented By The Department Of Health And Human Services Pigment epithelium-derived factor: characterization, genomic organization and sequence of PEDF gene
US5472856A (en) * 1993-12-21 1995-12-05 Immunobiology Research Institute, Inc. Recombinant human thymopoietin proteins and uses therefor
US5830686A (en) * 1994-01-13 1998-11-03 Calydon Tissue-specific enhancer active in prostate
US6867288B1 (en) * 1994-10-12 2005-03-15 Genzyme Corporation Polycystic kidney disease gene
US5830649A (en) * 1995-05-26 1998-11-03 Smithkline Beecham Corporation Human galactokinase gene
US5688927A (en) * 1995-06-07 1997-11-18 Icos Corporation Macrophage derived chemokine
US5965427A (en) * 1996-01-26 1999-10-12 Genelabs Technologies, Inc. Human RAD50 gene and methods of use thereof
US5872237A (en) * 1996-04-04 1999-02-16 Mercator Genetics, Inc. Megabase transcript map: novel sequences and antibodies thereto
US5645995A (en) * 1996-04-12 1997-07-08 Baylor College Of Medicine Methods for diagnosing an increased risk for breast or ovarian cancer

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
G. VANHOOF ET AL.: "Kininase activity in human platelets: cleavage of the Arg1-Pro2 bond of bradykinin by Aminopeptidase P." BIOCHEMICAL PHARMACOLOGY, vol. 44, no. 3, 4 August 1992, pages 479-487, XP002095035 cited in the application *
H-T. HARBECK ET AL.: "Aminopeptidase P from rat brain." EUR. J. BIOCHEM., vol. 198, no. 2, June 1991, pages 451-458, XP002095031 cited in the application *
HYDE, RALPH J. ET AL: "Molecular cloning and expression in COS-1 cells of pig kidney aminopeptidase P." BIOCHEMICAL JOURNAL, (1996) VOL. 319, NO. 1, PP. 197-201. ISSN: 0264-6021., XP002095024 *
I. RUSU ET AL.: "Aminopeptidase P from human leukocytes." EUR. J. BIOCHEM., vol. 210, no. 1, November 1992, pages 93-100, XP002095033 cited in the application *
JU, H. ET AL: "Aminopeptidase P in human tissues: Northern blot analysis." FASEB JOURNAL, (1997) VOL. 11, NO. 3, PP. A504. MEETING INFO.: ANNUAL MEETING OF THE PROFESSIONAL RESEARCH SCIENTISTS ON EXPERIMENTAL BIOLOGY 97 NEW ORLEANS, LOUISIANA, USA APRIL 6-9, 1997 ISSN: 0892-6638., XP002095025 *
LIM, JAESEUNG ET AL: "Chemical modification of porcine kidney aminopeptidase P indicates the involvement of two critical histidine residues." FEBS LETTERS, (1996) VOL. 381, NO. 3, PP. 188-190. ISSN: 0014-5793., XP002095029 *
LLOYD, GEORGINA S. ET AL: "Inhibition and metal ion activation of pig kidney aminopeptidase P. Dependence on nature of substrate." BIOCHEMICAL PHARMACOLOGY, (1996) VOL. 52, NO. 2, PP. 229-236. ISSN: 0006-2952., XP002095030 *
N.M. HOOPER ET AL.: "Purification and characterization of pig kidney aminopeptidase." BIOCHEM. J. , vol. 267, no. 2, 15 April 1990, pages 509-515, XP002095032 cited in the application *
RYAN, J. W. ET AL: "Immunoaffinity purifications of aminopeptidase P from guinea pig lungs, kidney and serum" BIOCHEM. BIOPHYS. RES. COMMUN. (1994), 205(3), 1796-802 CODEN: BBRCA9;ISSN: 0006-291X,1994, XP002095028 cited in the application *
SIDOROWICZ W ET AL: "KININ CLEAVAGE BY HUMAN ERYTHROCYTES." AM J HEMATOL, (1984) 17 (4), 383-392. CODEN: AJHEDD. ISSN: 0361-8609., XP002095026 *
VENEMA, RICHARD C. ET AL: "Cloning and tissue distribution of human membrane-bound aminopeptidase P." BIOCHIMICA ET BIOPHYSICA ACTA, (OCT. 9, 1997) VOL. 1354, NO. 1, PP. 45-48 ISSN: 0006-3002., XP002095023 *
W.H. SIMMONS ET AL.: "Membrane-bound Aminopeptidase P from Bovine lung." THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 267, no. 7, 5 March 1992, pages 4897-4903, XP002095034 cited in the application *

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001000811A3 (fr) * 1999-06-30 2001-03-22 Millennium Pharm Inc Nouvelle aminopeptidase humaine (17867)
US6362324B1 (en) 1999-06-30 2002-03-26 Millennium Pharmaceuticals, Inc. 17867 a novel human aminopeptidase
US7034111B2 (en) 1999-06-30 2006-04-25 Millennium Pharmaceuticals, Inc. 17867, a novel human aminopeptidase
US7977059B2 (en) 1999-06-30 2011-07-12 Millennium Pharmaceuticals, Inc. 17867, a novel human aminopeptidase
WO2001059134A1 (fr) * 2000-02-11 2001-08-16 Lexicon Genetics Incorporated Proteases humaines et polynucleotides codant pour elles
US6509456B2 (en) 2000-02-11 2003-01-21 Lexicon Genetics Incorporated Human proteases and polynucleotides encoding the same
US6881563B2 (en) 2000-02-11 2005-04-19 Lexicon Genetics Incorporated Human proteases and polynucleotides encoding the same
WO2002061131A3 (fr) * 2000-12-04 2003-06-19 Bristol Myers Squibb Co Polymorphismes de nucleotides simples humains
WO2004104595A2 (fr) * 2003-05-22 2004-12-02 Bayer Healthcare Ag Agents diagnostiques et therapeutiques destines a des maladies associees a la x-pro dipeptidase (pepd)
WO2004104595A3 (fr) * 2003-05-22 2005-04-28 Bayer Healthcare Ag Agents diagnostiques et therapeutiques destines a des maladies associees a la x-pro dipeptidase (pepd)

Also Published As

Publication number Publication date
WO1999011799A3 (fr) 1999-05-27
AU9303498A (en) 1999-03-22
US6399349B1 (en) 2002-06-04

Similar Documents

Publication Publication Date Title
Ku et al. Chronic hepatitis, hepatocyte fragility, and increased soluble phosphoglycokeratins in transgenic mice expressing a keratin 18 conserved arginine mutant.
Dong et al. Neurologic defects and selective disruption of basement membranes in mice lacking entactin-1/nidogen-1
Hutton et al. Functional differences between keratins of stratified and simple epithelia
AU752642B2 (en) Antibody against LAR phosphatase subunit
AU730705B2 (en) Human plasma hyaluronidase
Fuentes-Prior et al. New insights into binding interfaces of coagulation factors V and VIII and their homologues-lessons from high resolution crystal structures
EP0862625B1 (fr) Procede de modulation du transport de cholesterol
US5491075A (en) Cloning and expression of biologically active α-N-acetylgalactosaminidase
JP2001523081A (ja) プロビン チロシン キナーゼ（ＰＹＫ２）、そのｃＤＮＡクローニングおよびその用途
BRPI0906948B1 (pt) Composições compreendendo uma enzima nacetilgalactosamina-6- sulfatase (galns) recombinante humana e uso das mesmas para tratar mucopolissacaridose tipo iva, síndrome de morquio a, ou deficiência múltipla de sulfatase
JP2002505873A (ja) 血管内皮増殖因子２
US7695923B2 (en) CFTR polypeptides methods to overcome biosynthetic misprocessing
JP2003502046A (ja) 新規ヒト環状ヌクレオチドホスホジエステラーゼ
WO1999011799A2 (fr) Gene d'aminopeptidase p humaine
EP0585356A1 (fr) Clonage et expression de l'autoantigene decarboxylase de l'acide glutamique d'ilots humains
Li et al. Widespread tissue distribution of aminopeptidase A, an evolutionarily conserved ectoenzyme recognized by the BP‐1 antibody
Nagao et al. Mitochondrial carbonic anhydrase (isozyme V) in mouse and rat: cDNA cloning, expression, subcellular localization, processing, and tissue distribution.
Brooks et al. Glycosidase active site mutations in human α-L-iduronidase
Cohen Proteins of the systemic amyloidoses
JP2000512484A (ja) ヒト・ヒアルロナン・レセプター
WO2002068602A2 (fr) Methodes de modulation de l'activation d'un recepteur couple a la proteine g exprime par les lymphocytes et implique dans la proliferation cellulaire, l'auto-immunite et l'inflammation
O'Reilly et al. Studies on the thymus of non-obese diabetic (NOD) mice: effect of transgene expression
BIRDSEY et al. Evolution of alanine: glyoxylate aminotransferase intracellular targeting: structural and functional analysis of the guinea pig gene
JPH11507816A (ja) 再生している肝臓においてアップレギュレートされた新規な遺伝子
AU730141B2 (en) Transgenic animals with disrupted npy y1 receptor genes

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
NENP Non-entry into the national phase

Ref country code: KR

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载